Читать книгу Practical Cardiovascular Medicine - Elias B. Hanna - Страница 178

1 167. Delewi R,Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. Heart 2012; 98: 1743–9.

2 168. Shacham Y, Leshem-Rubinow E, Ben Ass E, et al. Frequency and correlates of early left ventricular thrombus formation following anterior wall acute myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 2013; 111: 667–70.

3 169. Asinger RW, Mikell FL, Elsperger J, et al. Incidence of left ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography. N Engl J Med 1981; 305: 297–302.

4 170. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta- analysis. J Am Coll Cardiol 1993; 22: 1004–9.

5 171. Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med 1986; 104: 689–98. +These 2 old studies: (a) Lapeyre AC 3rd, Steele PM, Kazmier FJ, et al. Systemic embolism in chronic left ventricular aneurysm: incidence and the role of anticoagulation. J Am Coll Cardiol 1985; 6(3):534-8. (b) Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc. 1981; 56(2):77–81.

6 172. Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002; 106: 2873–6.

7 173. Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol. 2020; 75(14):1676-1685.

8 174. Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol. 2020;5(6):685-692. For LV thrombus, NOACs are associated with 2.6 times higher thromboembolic risk compared to warfarin.